Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company that uses artificial intelligence and genomic data to develop precision oncology therapies, has closed its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share, generating approximately $4 million in gross proceeds before fees and expenses. The offering was made pursuant to a previously announced registered direct offering, and Rodman & Renshaw LLC acted as exclusive placement agent.
In a concurrent private placement, Lantern issued unregistered warrants to purchase up to an additional 3,669,725 shares at an exercise price of $1.09 per share, which could provide approximately $4 million in additional gross proceeds if fully exercised for cash. The company intends to use the net proceeds for working capital and other general corporate purposes, strengthening its financial position as it advances its pipeline of AI-driven cancer therapies. For more details, see the full press release.
Lantern Pharma is leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. This financing provides Lantern with additional resources to continue developing these programs, which could lead to more effective and personalized cancer treatments.
The announcement is significant for investors and the biopharma industry because it demonstrates continued financial support for AI-driven drug development, a field that promises to reduce the time and cost of bringing new cancer therapies to market. If Lantern's RADR platform succeeds in identifying responsive patient populations, it could improve clinical trial success rates and ultimately deliver better outcomes for patients. The offering also highlights the role of specialized communications platforms in disseminating such news to investors. NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. With broad reach and a seasoned team of contributing journalists and writers, NetworkNewsWire is uniquely positioned to serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
For Lantern Pharma, the successful closing of this offering provides non-dilutive capital (through warrants) and immediate funds to support its operations. The company's focus on AI and genomics positions it at the forefront of a growing trend in oncology drug development, where data-driven approaches are increasingly used to streamline research. As Lantern continues to advance its pipeline, the potential impact on patient care and the broader biotech investment landscape remains noteworthy. The latest news and updates relating to LTRN are available in the company's newsroom at https://nnw.fm/LTRN. For full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published, see https://www.NetworkNewsWire.com/Disclaimer.
